Alpha Teknova (NASDAQ:TKNO) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Alpha Teknova (NASDAQ:TKNO) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other research analysts have also recently weighed in on TKNO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. Roth Capital assumed coverage on Alpha Teknova in a research note on Wednesday. They issued a “buy” rating and a $7.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.00.

Alpha Teknova Price Performance

Shares of NASDAQ:TKNO opened at $6.46 on Friday. The company has a quick ratio of 3.60, a current ratio of 4.59 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $346.32 million, a PE ratio of -20.84 and a beta of 0.64. The firm’s 50 day moving average price is $5.23 and its 200-day moving average price is $3.75. Alpha Teknova has a twelve month low of $1.91 and a twelve month high of $6.68.

Alpha Teknova (NASDAQ:TKNO) last announced its earnings results on Wednesday, August 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. Alpha Teknova had a negative net margin of 38.37% and a negative return on equity of 24.38%. The company had revenue of $12.19 million during the quarter, compared to analyst estimates of $10.95 million. Equities research analysts expect that Alpha Teknova will post -0.28 EPS for the current year.

Institutional Investors Weigh In On Alpha Teknova

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TKNO. Roubaix Capital LLC boosted its position in shares of Alpha Teknova by 88.5% in the first quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company’s stock worth $5,440,000 after purchasing an additional 883,823 shares during the period. Royce & Associates LP purchased a new stake in shares of Alpha Teknova in the fourth quarter worth $1,116,000. Kestra Private Wealth Services LLC raised its position in shares of Alpha Teknova by 32.7% during the 4th quarter. Kestra Private Wealth Services LLC now owns 105,673 shares of the company’s stock valued at $402,000 after purchasing an additional 26,025 shares during the period. Conestoga Capital Advisors LLC raised its position in shares of Alpha Teknova by 2.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 317,084 shares of the company’s stock valued at $1,205,000 after purchasing an additional 8,145 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Alpha Teknova during the 2nd quarter valued at $604,000. Institutional investors own 13.81% of the company’s stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.